QuantHealth, founded in 2020, works with pharmaceutical companies, biotechs, and clinical research organizations, as well as regulators in the U.S. and Europe. The new funding will be used to support clinical development teams with its trial design solution, expand its platform for preclinical and drug discovery functions, and grow its commercial team and operations.
Key takeaways:
- QuantHealth, a Tel Aviv-based startup, has raised $15 million in a Series A funding round, bringing its total raised to $20 million. The company uses AI to predict risks and outcomes for clinical trials, aiming to streamline drug development.
- The company's platform claims to have one of the most extensive integrated datasets, covering over 350 million patients and more than 700,000 biomedical graphs and clinical trials. It can predict clinical trial outcomes with 86% accuracy on the binary endpoint metric.
- QuantHealth was founded in 2020 and works with pharma, biotechs, clinical research organizations, and regulators in the U.S. and Europe. The company recently announced its U.S. expansion and plans to grow its team to 40 by next year.
- The new funding will be used to support clinical development teams with its flagship trial design solution, expand its platform for preclinical and drug discovery functions, and grow its commercial team and operations.